Our study also suggests that USP29 and HIF1α are translational biomarkers for the prediction of therapy response in HCC patients, highlighting the USP29-HIF1α-glycolysis regulatory network as an emerging therapeutic target to overcome therapy resistance in HCC patients. This evidence concerns the gene HIF1A and hepatocellular carcinoma.